|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hunt JD, van der Hel OL, McMillan GP,
Boffetta P and Brennan P: Renal cell carcinoma in relation to
cigarette smoking: meta-analysis of 24 studies. Int J Cancer.
114:101–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellocco R, Pasquali E, Rota M, et al:
Alcohol drinking and risk of renal cell carcinoma: results of a
meta-analysis. Ann Oncol. 23:2235–2244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bjørge T, Tretli S and Engeland A:
Relation of height and body mass index to renal cell carcinoma in
two million Norwegian men and women. Am J Epidemiol. 160:1168–1176.
2004.PubMed/NCBI
|
|
6
|
Bergström A, Hsieh CC, Lindblad P, Lu CM,
Cook NR and Wolk A: Obesity and renal cell cancer - a quantitative
review. Br J Cancer. 85:984–990. 2001.
|
|
7
|
McLaughlin JK, Chow WH, Mandel JS, et al:
International renal-cell cancer study. VIII Role of diuretics,
other anti-hypertensive medications and hypertension. Int J Cancer.
63:216–221. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrara N: Vascular endothelial growth
factor. Trends Cardiovasc Med. 3:244–250. 1993. View Article : Google Scholar
|
|
9
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
10
|
Zhou LP, Luan H, Dong XH, Jin GJ, Man DL
and Shang H: Vascular endothelial growth factor +936C/T
polymorphism and gastric cancer risk: A meta-analysis. Exp Ther
Med. 2:931–936. 2011.
|
|
11
|
Kleinrouweler CE, Wiegerinck MM,
Ris-Stalpers C, et al; EBM CONNECT Collaboration. Accuracy of
circulating placental growth factor, vascular endothelial growth
factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in
the prediction of pre-eclampsia: a systematic review and
meta-analysis. BJOG. 119:778–787. 2012. View Article : Google Scholar
|
|
12
|
Toulis KA, Goulis DG, Mintziori G, et al:
Meta-analysis of cardiovascular disease risk markers in women with
polycystic ovary syndrome. Hum Reprod Update. 17:741–760. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lambrechts D, Poesen K, Fernández-Santiago
R, et al: Meta-analysis of vascular endothelial growth factor
variations in amyotrophic lateral sclerosis: increased
susceptibility in male carriers of the −2578AA genotype. J Med
Genet. 46:840–846. 2009.PubMed/NCBI
|
|
14
|
Banumathy G and Cairns P: Signaling
pathways in renal cell carcinoma. Cancer Biol Ther. 10:658–664.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abe A, Sato K, Habuchi T, et al: Single
nucleotide polymorphisms in the 3′ untranslated region of vascular
endothelial growth factor gene in Japanese population with or
without renal cell carcinoma. Tohoku J Exp Med. 198:181–190.
2002.
|
|
16
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. BMJ. 339:b25352009.
View Article : Google Scholar
|
|
17
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ricketts C, Zeegers MP, Lubinski J and
Maher ER: Analysis of germline variants in CDH1, IGFBP3, MMP1,
MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.
PLoS One. 4:e60372009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bruyère F, Hovens CM, Marson MN, et al:
VEGF polymorphisms are associated with an increasing risk of
developing renal cell carcinoma. J Urol. 184:1273–1278.
2010.PubMed/NCBI
|
|
21
|
Ajaz S, Khaliq S, Abid A, et al:
Association of a single-nucleotide polymorphism in the promoter
region of the VEGF gene with the risk of renal cell carcinoma.
Genet Test Mol Biomarkers. 15:653–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sáenz-Lopez P, Vazquez F, Cozar JM,
Carretero R, Garrido F and Ruiz-Cabello F: VEGF polymorphisms are
not associated with an increased risk of developing renal cell
carcinoma in Spanish population. Hum Immunol. 74:98–103. 2013.
|
|
23
|
Lutty GA, McLeod DS, Merges C, Diggs A and
Plouét J: Localization of vascular endothelial growth factor in
human retina and choroid. Arch Ophthalmol. 114:971–977. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vincenti V, Cassano C, Rocchi M and
Persico MG: Assignment of the vascular endothelial growth factor
gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996.
View Article : Google Scholar
|
|
25
|
Neufeld G, Cohen T, Gengrinovitch S and
Poltorak Z: Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13:9–22. 1999.PubMed/NCBI
|
|
26
|
Shahbazi M, Fryer AA, Pravica V, et al:
Vascular endothelial growth factor gene polymorphisms are
associated with acute renal allograft rejection. J Am Soc Nephrol.
13:260–264. 2002.PubMed/NCBI
|
|
27
|
Lambrechts D, Storkebaum E, Morimoto M, et
al: VEGF is a modifier of amyotrophic lateral sclerosis in mice and
humans and protects motoneurons against ischemic death. Nat Genet.
34:383–394. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Renner W, Kotschan S, Hoffmann C,
Obermayer-Pietsch B and Pilger E: A common 936 C/T mutation in the
gene for vascular endothelial growth factor is associated with
vascular endothelial growth factor plasma levels. J Vasc Res.
37:443–448. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krippl P, Langsenlehner U, Renner W, et
al: A common 936 C/T gene polymorphism of vascular endothelial
growth factor is associated with decreased breast cancer risk. Int
J Cancer. 106:468–471. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Watson CJ, Webb NJ, Bottomley MJ and
Brenchley PE: Identification of polymorphisms within the vascular
endothelial growth factor (VEGF) gene: correlation with variation
in VEGF protein production. Cytokine. 12:1232–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lam JS, Leppert JT, Figlin RA and
Belldegrun AS: Role of molecular markers in the diagnosis and
therapy of renal cell carcinoma. Urology. 66:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haviv YS and Curiel DT: Gene therapy for
renal cancer. Contrib Nephrol. 159:135–150. 2008. View Article : Google Scholar
|
|
33
|
Hainsworth JD, Sosman JA, Spigel DR,
Edwards DL, Baughman C and Greco A: Treatment of metastatic renal
cell carcinoma with a combination of bevacizumab and erlotinib. J
Clin Oncol. 23:7889–7896. 2005. View Article : Google Scholar : PubMed/NCBI
|
